Dr. Reddy's Laboratories Ltd ADR (RDY)

$13.94 +0.07 (0.50%)
Market Cap 11.58B
Revenue (ttm) 3.81B
Net Income (ttm) 663.00M
EPS (ttm) N/A
PE Ratio 17.10
Forward PE 19.79
Profit Margin 17.40%
Debt to Equity Ratio 0.16
Volume 893,900
Avg Vol 1,061,822
Day's Range N/A - N/A
Shares Out 834.93M
Stochastic %K 88%
Beta 0.37
Analysts Hold
Price Target $16.20

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equival...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
BigBreakingWire
BigBreakingWire Nov. 9 at 6:01 AM
Dr. Reddy’s Laboratories Hit by ₹2.16 Crore Cyber Fraud — Key Points: Dr. Reddy’s Laboratories lost ₹2.16 crore after transferring funds to a fraudulent account. Hackers impersonated Group Pharmaceutical Ltd. executives using a spoofed email — ‘[email protected]’ (fake) instead of ‘[email protected]’ (real). The fraudsters gained access to genuine email communication between both companies. The payment was diverted to a fake Bank of Baroda account. Group Pharmaceutical filed an FIR with Bengaluru City Cyber Crime Police, seeking freezing and recovery of funds. The case was registered under IT Act sections for identity theft and cheating by personation, with the accused located in Vadodara, Gujarat. $DRREDDY.NSE $RDY $NIFTY50.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 30 at 2:40 PM
$RDY Share Price: $13.48 Contract Selected: Jun 18, 2026 $15 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.27 – $0.33 Potential Upside: 52% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 4:19 PM
$RDY beats earnings estimates — but why is the stock still struggling? Shares have fallen 7.6% YTD despite a 9.8% revenue boost, primarily driven by global generics revenues. 🇪🇺 Positive CHMP opinion for AVT03 biosimilar could significantly impact future revenue if approved by the European Commission. Full analysis here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-body-17810&ADID=SYND_STOCKTWITS_TWEET_2_2778024_BODY_17810
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 3:19 PM
$RDY beats Q2 expectations — generics power the surge Strong global generics demand lifted both earnings and revenue, while new launches and biosimilar progress are fueling future momentum. Full Q2 breakdown and growth drivers here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-teaser-17780&ADID=SYND_STOCKTWITS_TWEET_2_2778024_TEASER_17780
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $RDY $COF $USB $VZLA AA
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 8:22 PM
$RDY Really good write-up that perfectly summarizes RDY's present situation. So if you want to bring your RDY knowledge up to date or just discover RDY, this is required reading. https://beyondspx.com/quote/RDY/analysis/dr-reddy-s-innovation-and-diversification-powering-future-growth-amidst-generic-headwinds-rdy
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 2:21 PM
$ESPR surged 13.8% on settlement news with $RDY! 🚀 Esperion clinched a deal preventing RDY’s generic launches of Nexletol/Nexlizet until 2040, except under certain conditions, resolving patent disputes and boosting investor confidence. 📈 With a 50% YTD rise, ESPR is outpacing the industry’s 14.1% growth. Find out what this means for future growth 👉 https://www.zacks.com/stock/news/2762841/espr-settles-nexletolnexlizet-patent-litigation-with-rdy-stock-up?cid=sm-stocktwits-2-2762841-body-14760&ADID=SYND_STOCKTWITS_TWEET_2_2762841_BODY_14760
1 · Reply
WallStWireAds
WallStWireAds Aug. 30 at 12:22 PM
$DRREDDY.NSE $RDY https://capnotes.beehiiv.com/p/dr-reddy-s-multi-lever-strategy-to-power-its-next-phase-of-growth
0 · Reply
G101SPM
G101SPM Aug. 7 at 10:45 AM
#NOISE According to SPM tag, India Prime Minister Narendra Modi says he will not compromise on tariffs. In-play: $RDY, $INFY, $WIT, $INDA
0 · Reply
WallStWireAds
WallStWireAds Aug. 2 at 3:45 PM
$RDY https://alphacatalyst.beehiiv.com/p/dr-reddy-s-reports-record-revenues-in-q1-signals-steady-execution-through-transition-year
0 · Reply
Latest News on RDY
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Oct 29, 2025, 2:02 PM EDT - 16 days ago

Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript

Oct 24, 2025, 6:57 PM EDT - 21 days ago

Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Aug 18, 2025, 8:16 AM EDT - 3 months ago

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript

Jul 23, 2025, 6:09 PM EDT - 4 months ago

Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript

Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 4 months ago

Dr. Reddy's Q1FY26 Financial Results

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Jul 23, 2025, 10:27 AM EDT - 4 months ago

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Jun 5, 2025, 1:56 PM EDT - 5 months ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

ALVO MRK

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Jun 5, 2025, 7:00 AM EDT - 5 months ago

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Dr. Reddy's Continues To Be A Good Buy At Current Valuation

May 15, 2025, 11:47 AM EDT - 6 months ago

Dr. Reddy's Continues To Be A Good Buy At Current Valuation

Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

May 12, 2025, 3:51 AM EDT - 6 months ago

Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript

May 9, 2025, 6:03 PM EDT - 6 months ago

Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript

Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 6 months ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

Apr 9, 2025, 3:59 PM EDT - 7 months ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Mar 27, 2025, 11:47 AM EDT - 8 months ago

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Mar 18, 2025, 8:35 AM EDT - 8 months ago

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Mar 13, 2025, 10:40 AM EDT - 8 months ago

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Feb 6, 2025, 7:51 AM EST - 10 months ago

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Feb 6, 2025, 6:35 AM EST - 10 months ago

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns

Jan 30, 2025, 6:56 AM EST - 10 months ago

Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns

Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript

Jan 23, 2025, 3:58 PM EST - 10 months ago

Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript

Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 10 months ago

Dr. Reddy's Q3 & 9MFY25 Financial Results

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Nov 28, 2024, 6:15 AM EST - 1 year ago

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Nov 26, 2024, 8:07 AM EST - 1 year ago

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript

Nov 5, 2024, 1:26 PM EST - 1 year ago

Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript

Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Oct 25, 2024, 7:40 AM EDT - 1 year ago

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Oct 14, 2024, 9:47 AM EDT - 1 year ago

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Oct 8, 2024, 11:32 AM EDT - 1 year ago

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Oct 2, 2024, 11:10 AM EDT - 1 year ago

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Aug 20, 2024, 2:42 PM EDT - 1 year ago

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Aug 13, 2024, 1:33 AM EDT - 1 year ago

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Dr. Reddy's Laboratories: India 'will be our number one market'

Jul 30, 2024, 8:25 PM EDT - 1 year ago

Dr. Reddy's Laboratories: India 'will be our number one market'

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Jul 29, 2024, 11:55 AM EDT - 1 year ago

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 1 year ago

Dr. Reddy's Q1FY25 Financial Results

Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Jun 26, 2024, 11:26 AM EDT - 1 year ago

Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

Jun 3, 2024, 1:05 PM EDT - 1 year ago

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

May 28, 2024, 9:53 AM EDT - 1 year ago

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 21, 2024, 10:05 AM EDT - 1 year ago

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript

May 7, 2024, 2:42 PM EDT - 1 year ago

Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript

Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 7, 2024, 10:31 AM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results

Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.

May 3, 2024, 8:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13, 2024, 8:25 AM EST - 1 year ago

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

COYA

Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 31, 2024, 9:44 AM EST - 1 year ago

Dr. Reddy's Q3 & 9M FY24 Financial Results

Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript

Jan 30, 2024, 3:50 PM EST - 1 year ago

Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands

Jan 3, 2024, 6:00 AM EST - 2 years ago

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands

Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Dec 14, 2023, 7:49 AM EST - 2 years ago

Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 6, 2023, 7:00 AM EST - 2 years ago

Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

COYA

India's Dr. Reddy's R&D centre being inspected by US FDA

Dec 5, 2023, 4:41 AM EST - 2 years ago

India's Dr. Reddy's R&D centre being inspected by US FDA

BigBreakingWire
BigBreakingWire Nov. 9 at 6:01 AM
Dr. Reddy’s Laboratories Hit by ₹2.16 Crore Cyber Fraud — Key Points: Dr. Reddy’s Laboratories lost ₹2.16 crore after transferring funds to a fraudulent account. Hackers impersonated Group Pharmaceutical Ltd. executives using a spoofed email — ‘[email protected]’ (fake) instead of ‘[email protected]’ (real). The fraudsters gained access to genuine email communication between both companies. The payment was diverted to a fake Bank of Baroda account. Group Pharmaceutical filed an FIR with Bengaluru City Cyber Crime Police, seeking freezing and recovery of funds. The case was registered under IT Act sections for identity theft and cheating by personation, with the accused located in Vadodara, Gujarat. $DRREDDY.NSE $RDY $NIFTY50.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 30 at 2:40 PM
$RDY Share Price: $13.48 Contract Selected: Jun 18, 2026 $15 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.27 – $0.33 Potential Upside: 52% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 4:19 PM
$RDY beats earnings estimates — but why is the stock still struggling? Shares have fallen 7.6% YTD despite a 9.8% revenue boost, primarily driven by global generics revenues. 🇪🇺 Positive CHMP opinion for AVT03 biosimilar could significantly impact future revenue if approved by the European Commission. Full analysis here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-body-17810&ADID=SYND_STOCKTWITS_TWEET_2_2778024_BODY_17810
0 · Reply
ZacksResearch
ZacksResearch Oct. 27 at 3:19 PM
$RDY beats Q2 expectations — generics power the surge Strong global generics demand lifted both earnings and revenue, while new launches and biosimilar progress are fueling future momentum. Full Q2 breakdown and growth drivers here 👉 https://www.zacks.com/stock/news/2778024/dr-reddys-q2-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2778024-teaser-17780&ADID=SYND_STOCKTWITS_TWEET_2_2778024_TEASER_17780
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $RDY $COF $USB $VZLA AA
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 8:22 PM
$RDY Really good write-up that perfectly summarizes RDY's present situation. So if you want to bring your RDY knowledge up to date or just discover RDY, this is required reading. https://beyondspx.com/quote/RDY/analysis/dr-reddy-s-innovation-and-diversification-powering-future-growth-amidst-generic-headwinds-rdy
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 2:21 PM
$ESPR surged 13.8% on settlement news with $RDY! 🚀 Esperion clinched a deal preventing RDY’s generic launches of Nexletol/Nexlizet until 2040, except under certain conditions, resolving patent disputes and boosting investor confidence. 📈 With a 50% YTD rise, ESPR is outpacing the industry’s 14.1% growth. Find out what this means for future growth 👉 https://www.zacks.com/stock/news/2762841/espr-settles-nexletolnexlizet-patent-litigation-with-rdy-stock-up?cid=sm-stocktwits-2-2762841-body-14760&ADID=SYND_STOCKTWITS_TWEET_2_2762841_BODY_14760
1 · Reply
WallStWireAds
WallStWireAds Aug. 30 at 12:22 PM
$DRREDDY.NSE $RDY https://capnotes.beehiiv.com/p/dr-reddy-s-multi-lever-strategy-to-power-its-next-phase-of-growth
0 · Reply
G101SPM
G101SPM Aug. 7 at 10:45 AM
#NOISE According to SPM tag, India Prime Minister Narendra Modi says he will not compromise on tariffs. In-play: $RDY, $INFY, $WIT, $INDA
0 · Reply
WallStWireAds
WallStWireAds Aug. 2 at 3:45 PM
$RDY https://alphacatalyst.beehiiv.com/p/dr-reddy-s-reports-record-revenues-in-q1-signals-steady-execution-through-transition-year
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
Flrz
Flrz Jul. 26 at 8:21 AM
$RDY
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 4:23 PM
$RDY Q1 earnings beat — but is the stock a buy? EPS of 20 cents per ADS topped the Zacks Consensus Estimate of 18 cents. Revenues grew 11% year over year to $997 million, driven by growth in global generics revenues, surpassing estimates. Yet, shares have slipped 7.5% year to date. Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-body-3688&ADID=SYND_STOCKTWITS_TWEET_2_2613023_BODY_3688
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 2:34 PM
$RDY beats Q1 estimates — generics driving the surge Earnings and revenue both came in above expectations, powered by strong growth in global generic sales. See what could drive RDY’s next move 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-teaser-3564&ADID=SYND_STOCKTWITS_TWEET_2_2613023_TEASER_3564
0 · Reply
XkaliburTrading
XkaliburTrading Jul. 23 at 6:46 PM
$RDY https://benzinga.com/node/46581767
0 · Reply
WallStWireAds
WallStWireAds Jul. 18 at 3:45 PM
$RDY $DRREDDY.NSE https://thefinanceherald.com/expanding-the-preventive-care-frontier-dr-reddys-launches-sanofis-beyfortus-in-india/
0 · Reply
DougAfter60
DougAfter60 Jul. 18 at 1:40 PM
let’s see if $RDY is due for a run
0 · Reply
infront
infront Jun. 17 at 10:16 PM
$RDY https://finance.yahoo.com/news/teva-partners-fosun-develop-tev-160200038.html
0 · Reply
Flrz
Flrz Jun. 12 at 8:17 PM
$RDY I am ready :)
0 · Reply
Nomorelies
Nomorelies Jun. 10 at 2:56 PM
$RDY That’s quite an upgrade!!
0 · Reply
infront
infront Jun. 6 at 12:12 PM
$RDY https://www.streetinsider.com/dr/news.php?id=24905974&gfv=1
0 · Reply
ZacksResearch
ZacksResearch Jun. 5 at 4:46 PM
$RDY just landed a key biosimilar deal — here's why it matters 👇 Partnering with Alvotech to co-develop and commercialize a biosimilar version of $MRK’s blockbuster Keytruda, expanding its reach in the high-growth biosimilars market. See what this could mean for RDY’s pipeline and growth outlook 👉 https://www.zacks.com/stock/news/2485940/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar?cid=sm-stocktwits-2-2485940-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2485940_TEASER
0 · Reply